**Table S1** Disease activity and function before and after weight-loss treatment in the 29 patients with PsA who didn´t have minimal disease activity at baseline.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Baseline**Median (IQR)Min- Max | **6 months**Median (IQR)Min- Max | **p-value** |
| **Weight, kg**  | 105.0 (95.8-115.8)84-124 | 82.1 (75.9-90.9)61.3-104.3 | <0.001 |
| **BMI, kg/m2** | 36.0 (34.5-39.3)32.6-45.8 | 29.8 (27.2-31.7)23.1-37.0 | <0.001 |
| **Waist circumference, cm** | 117 (108-122)103-135 | 95 (90-101)81-116 | <0.001 |
| **CRP, mg/L** | 5 (3- 11)1-50 | 5 (2-9)1-50 | 0.135 |
| **Hemoglobin, g/L** | 138 (130-146)116-168 | 136 (131-144)118-161 |  0.156 |
| **WBC, 109/L** | 6.2 (5.4-7.6)4.3-15.2 | 6.0 (4.9-7.6)(3.8-12.7) | 0.112 |
| **PLT, 109/L** | 271 (208-316)174-444 | 264 (196-299)156-402 | 0.001 |
| **Tender joints 68, score** |  8 (3-18)0-30 | 6 (1-8)0-19 | <0.001 |
| **Swollen joints 66, score** | 0 (0-2)0-5 | 0 (0-0.5)0-1 | 0.040 |
| **VAS Patients global disease activity, mm** | 45 (31-69)18-93 | 23 (10-60)0-95 | 0.002 |
| **VAS Pain, mm** | 57 (26-70)16-95 | 28 (14-60)0-95 | 0.003 |
| **VAS Fatigue, mm** | 62 (49-72)12-94 | 30 (8-49)0-98 | <0.001 |
| **DAS28CRP, score** | 3.4 (2.9-4.3)2.2-5.6 | 2.9 (2.0-3.5)1.3-4.5 | <0.001 |
| **DAPSA, score** | 20 (12.6-33.2)6.7- 46 | 12.1 (6.4-22.4)0.9- 35.2 | <0.001 |
| **Leeds enthesitis index** | 3 (0-4)0-6 | 2 (0-3)0-4 | 0.003 |
| **BSA, %** | 0.5 (0-2.5)0-7 | 0.5 (0-2.0)0-4 | 0.031 |
| **HAQ, score** | 0.75 (0.50- 1.19)0-2.63 | 0.38 (0.19- 0.88)0-1.88 | 0.001 |
| **DLQI, score** | 1 (0-5.5)0-17 | 1 (0-4)0-20 | 0.292 |

BMI = Body Mass Index, BSA = Body Surface Area, CRP = C- reactive protein, DAPSA = Disease Activity in PSoriatic Arthritis, DAS28CRP = Disease Activity Score using 28 joint counts based on CRP, DLQI = Dermatology Life Quality Index, PLT = platelet count, WBC = white blood cell count